Massive study tracks Real-Life outcomes for 1000 lymphoma patients
NCT ID NCT04837222
Summary
This study aims to collect real-world information on the safety and effectiveness of the drug brentuximab vedotin for patients with CD30-positive lymphoma. It will follow about 1000 patients in China who are already receiving this treatment as part of their standard care. The goal is to understand how the drug works and what side effects occur in everyday medical practice, not to test a new treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Affiliated Hodpital of Nantong University
Nantong, Jiangsu, 226001, China
-
Anhui Provincial Cancer Hospital
Hefei, Anhui, 230001, China
-
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, 200032, China
-
Hematology Hospital of Chinese Academy of Medical Sciences
Tianjin, Tianjin Municipality, 300020, China
-
HenanProvincial CancerHospital
Zhengzhou, Henan, 450003, China
-
Jiangsu Province Hospital
Nanjing, Jiangsu, 210029, China
-
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, 100010, China
-
Peking University People's Hospital
Beijing, Beijing Municipality, 100044, China
-
Peking University Shenzhen Hospital
Shenzhen, Guangdong, 518035, China
-
Peking University Third Hospita
Beijing, Beijing Municipality, 100191, China
-
Qilu Hospital of Shandong University
Jinan, Shandong, 250012, China
-
Ruijin Hospital affiliated to Shanghai Jiaotong University School of Medicine
Shanghai, Shanghai Municipality, 200025, China
-
ShandongProvincial CancerHospital
Jinan, Shandong, 250117, China
-
ShanxiProvincial CancerHospital
Taiyuan, Shanxi, 030013, China
-
The Affiliated People's Hospital of Ningbo University
Ningbo, Zhejiang, 315040, China
-
The First Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, 510280, China
-
The First Affiliated Hospital of Henan University of Science and Technology
Luoyang, Henan, 471003, China
-
The First Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, 330006, China
-
The First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, 215006, China
-
The First Affiliated Hospital of Xiamen University
Xiamen, Fujian, 361003, China
-
The Fourth Hospital of Hebei Medical University
Shijiazhuang, Hebei, 050011, China
-
The Second Affiliated Hospital Zhejiang University School of Medicine
Hangzhou, Zhejiang, 310052, China
-
The Second Hospital of Dalian Medical University
Dalian, Liaoning, 116027, China
-
The first hospital of Jilin University
Changchun, Jilin, 130021, China
-
Tianjin Medical University Cancer Institute & Hospital
Tianjin, Tianjin Municipality, 300060, China
-
Tianjin People's Hospital
Tianjin, Tianjin Municipality, 300121, China
-
Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology
Wuhan, Hubei, 430022, China
-
Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology
Wuhan, Hubei, 430023, China
-
West China Hospital of Sichuan University
Chengdu, Sichuan, 610041, China
-
Yunnan First People's Hospital
Kunming, Yunnan, 650032, China
-
Zhongda Hospital Southeast University
Nanjing, Jiangsu, 210009, China
-
ZhuJiang Hosptital of Southern Medical University
Guangzhou, Guangdong, 510280, China
Conditions
Explore the condition pages connected to this study.